Don’t miss the Q4 2016 update of RealTime Dynamix: Multiple Sclerosis, the sixth edition in an on-going series. We highlight responses from 100 neurologists about the evolving treatment patterns for disease-modifying therapies in MS. Emphasis on market shifts resulting from the introduction of Glatopa, the first generic DMT to enter the market, early indicators of likely uptake of Roche’s Ocrevus and which DMTs face the greatest threat and where AbbVie/Biogen’s Zinbryta will find its place in the treatment paradigm. This report offers a balance of trending metrics with fresh new content each quarter and helps clients stay up to date on this highly competitive and dynamic market.
About Spherix Global Insights
Spherix Global Insights is a business intelligence and market research company, specializing in renal, autoimmune, neurologic and rare disease markets. Our aim is to apply our commercial experience and unique relationships within core specialty markets to translate data into insight, enabling our clients to make smarter business decisions.